LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

Search

Quidel Corp

Închisă

21.84 3.46

Rezumat

Modificarea prețului

24h

Curent

Minim

20.81

Maxim

22.12

Indicatori cheie

By Trading Economics

Angajați

6,600

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+45.12% upside

Dividende

By Dow Jones

Următoarele câștiguri

6 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-285M

1.4B

Deschiderea anterioară

18.38

Închiderea anterioară

21.84

Quidel Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 feb. 2026, 23:07 UTC

Câștiguri

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 feb. 2026, 23:01 UTC

Câștiguri

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 feb. 2026, 22:59 UTC

Câștiguri

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24 feb. 2026, 22:42 UTC

Câștiguri

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24 feb. 2026, 22:24 UTC

Achiziții, Fuziuni, Preluări

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24 feb. 2026, 23:48 UTC

Câștiguri

OCBC's Fourth-Quarter Net Profit Rose on Higher Non-Interest Income

24 feb. 2026, 23:46 UTC

Market Talk

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24 feb. 2026, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24 feb. 2026, 23:30 UTC

Market Talk

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24 feb. 2026, 23:20 UTC

Market Talk

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24 feb. 2026, 23:20 UTC

Market Talk

Global Equities Roundup: Market Talk

24 feb. 2026, 23:16 UTC

Câștiguri

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24 feb. 2026, 23:13 UTC

Câștiguri

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24 feb. 2026, 23:12 UTC

Câștiguri

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24 feb. 2026, 23:10 UTC

Câștiguri

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24 feb. 2026, 23:10 UTC

Câștiguri

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24 feb. 2026, 23:08 UTC

Câștiguri

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24 feb. 2026, 23:07 UTC

Câștiguri

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24 feb. 2026, 22:52 UTC

Câștiguri

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 feb. 2026, 22:46 UTC

Câștiguri

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 feb. 2026, 22:31 UTC

Achiziții, Fuziuni, Preluări

Warner Receives New Bid From Paramount -- 3rd Update

24 feb. 2026, 22:29 UTC

Câștiguri

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24 feb. 2026, 22:28 UTC

Câștiguri

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24 feb. 2026, 22:27 UTC

Câștiguri

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24 feb. 2026, 22:27 UTC

Câștiguri

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24 feb. 2026, 22:25 UTC

Câștiguri

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24 feb. 2026, 22:24 UTC

Câștiguri

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24 feb. 2026, 22:23 UTC

Câștiguri

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24 feb. 2026, 22:22 UTC

Câștiguri

Woolworths Interim Dividend 45 Australian Cents/Share

24 feb. 2026, 22:22 UTC

Câștiguri

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

Comparație

Modificare preț

Quidel Corp Așteptări

Obiectiv de preț

By TipRanks

45.12% sus

Prognoză pe 12 luni

Medie 30.75 USD  45.12%

Maxim 38 USD

Minim 25 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruQuidel Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

5 ratings

1

Cumpărare

3

Păstrare

1

Vânzare

Date financiare

$

Despre Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat